NEUROPACE, INC. (NPCE) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$5.14M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$5.57M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$2.60M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$8.19M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$5.14M | (m) | $22.83M | (m) | $125.00K* | -$3.90M* | $3.92M | $6.90M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$5.57M | (m) | $22.07M | (m) | $117.00K | -$5.90M | $4.02M | $7.19M | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$2.60M | (m) | $27.35M | (m) | $30.00K* | -$1.94M* | $6.19M | $6.58M | (m) | $0.00 |
| 2025-06-30 | Reported | (m) | -$8.19M | (m) | $19.50M | (m) | $168.00K* | -$2.09M* | $3.29M | $6.84M | (m) | $0.00 |
| 2025-03-31 | Reported | (m) | -$5.15M | (m) | $22.52M | (m) | $37.00K | -$7.48M | $5.18M | $7.44M | $15.05M | $0.00 |
| 2024-09-30 | Reported | (m) | -$4.24M | (m) | $21.06M | (m) | $100.00K* | -$1.72M* | $5.64M | $5.75M | $13.91M | $0.00 |
| 2024-06-30 | Reported | (m) | -$6.23M | (m) | $19.26M | (m) | $63.00K* | -$3.90M* | $5.12M | $6.07M | $14.30M | $0.00 |
| 2024-03-31 | Reported | (m) | -$7.54M | (m) | $18.12M | (m) | $104.00K | -$7.53M | $4.78M | $5.78M | $15.10M | $0.00 |
| 2023-09-30 | Reported | (m) | -$5.95M | (m) | $16.43M | (m) | $9.00K* | -$2.30M* | $4.19M | $4.79M | $13.39M | $0.00 |
| 2023-06-30 | Reported | (m) | -$7.85M | (m) | $16.51M | (m) | $0.00* | -$4.36M* | $4.54M | $5.34M | $14.48M | $0.00 |
| 2023-03-31 | Reported | (m) | -$8.32M | (m) | $14.47M | (m) | $132.00K | -$9.70M | $4.10M | $5.26M | $13.43M | $0.00 |
| 2022-09-30 | Reported | (m) | -$10.20M | (m) | $11.16M | (m) | $31.00K* | -$6.97M* | $3.19M | $5.61M | $12.55M | $0.00 |
| 2022-06-30 | Reported | (m) | -$10.97M | (m) | $10.20M | (m) | $164.00K* | -$10.66M* | $2.73M | $5.67M | $12.77M | $0.00 |
| 2022-03-31 | Reported | (m) | -$9.76M | (m) | $11.37M | (m) | $306.00K | -$11.39M | $3.12M | $5.58M | $12.44M | $0.00 |
| 2021-09-30 | Reported | (m) | -$6.24M | (m) | $10.34M | (m) | $178.00K* | -$4.42M* | $2.83M | $4.33M | $9.42M | $0.00 |
| 2021-06-30 | Reported | (m) | -$4.61M | (m) | $12.63M | (m) | $17.00K* | -$6.01M* | $3.27M | $4.44M | $9.53M | $0.00 |
| 2021-03-31 | Reported | (m) | -$3.87M | (m) | $11.22M | (m) | $35.00K | -$5.94M | $2.72M | $4.10M | $8.27M | $0.00 |
| 2020-09-30 | Reported | (m) | -$1.17M | (m) | $12.77M | (m) | $0.00* | -$5.42M* | $3.20M | $3.69M | $7.05M | $0.00 |
| 2020-06-30 | Reported | (m) | -$3.45M | (m) | $7.64M | (m) | $0.00* | -$3.21M* | $2.22M | $3.25M | $5.62M | $0.00 |
| 2020-03-31 | Reported | (m) | -$5.46M | (m) | $9.97M | (m) | $16.00K | -$6.55M | $2.92M | $4.83M | $7.68M | $0.00 |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$16.34M | (m) | $99.99M | (m) | $332.00K | -$11.01M | $22.77M | $27.89M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$21.67M | (m) | $79.91M | (m) | $306.00K | -$17.95M | $20.82M | $23.65M | $57.10M | (m) |
| 2023-12-31 | Reported | (m) | -$27.17M | (m) | $65.42M | (m) | $173.00K | -$19.70M | $17.30M | $20.78M | $54.52M | (m) |
| 2022-12-31 | Reported | (m) | -$40.79M | (m) | $45.52M | (m) | $603.00K | -$36.87M | $13.03M | $21.95M | $51.34M | (m) |
| 2021-12-31 | Reported | (m) | -$23.74M | (m) | $45.18M | (m) | $384.00K | -$24.58M | $11.75M | $18.21M | $38.96M | (m) |
| 2020-12-31 | Reported | (m) | -$13.05M | (m) | $41.14M | (m) | $62.00K | -$21.61M | $10.87M | $15.70M | $27.63M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |